Trial reportPlant foods for human nutrition (Dordrecht, Netherlands)2025
Effects of Sacha Inchi (Plukenetia volubilis L.) Oil Supplementation on Hyperglycaemia, Hypertension and Hyperlipidaemia (3Hs) Patients: A Preliminary Human Trial.
Trial report in Plant foods for human nutrition (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sacha Inchi oil (SIO), derived from seeds of Plukenetia volubilis L., is a novel plant source of unsaturated fatty acids, highly regarded for its health benefits. The rich fractions of polyunsaturated fatty acids have shown potential in improving or reducing the impact of hyperglycaemia, hypertension and hyperlipidaemia (3Hs) for both in vivo and preliminary human studies. This study aimed to investigate the effects of SIO supplementation on glycaemic, lipid and blood pressures outcomes of patients with 3Hs. A randomised, double-blind, placebo-controlled human clinical trial was conducted to investigate the effects of SIO supplementation in fifty-four (n = 54) 3Hs patients. Assessments of glycaemic control, blood pressure and lipid profiles were conducted and compared at baseline and week-12 after 3Hs patients were randomised into SIO group (n = 27) (received 1000 mg of SIO soft gel per day) or the placebo group (n = 27) (received 1000 mg of corn oil), with prescribed medications. The compliancy and tolerability of supplementation were assessed concurrently. The SIO group demonstrated lower systolic (-8.6 mmHg, p = 0.004) and diastolic blood pressure (BP) (-7.0 mmHg, p = 0.004), total cholesterol (TC) (-0.6 mmol/L, p = 0.024), low density lipoprotein-cholesterol (LDL-C) (-0.3 mmol/L, p = 0.036) and high density lipoprotein-cholesterol (HDL-C) (p = 0.048) but no effect on glycaemic markers. No clinical adverse events were reported, and the side effects of SIO supplementation were self-limiting and minimal. SIO supplementation showed the potential to alleviate BPs, reduced both TC and LDL-C, and improved HDL-C levels. SIO may offer a simple, novel complementary medicine for the management of 3Hs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.